Merit Medical Reports Second Quarter 2024 Results and Raises Full-Year Guidance

 Second Quarter 2024 Highlights†

• Reported revenue of $338.0 million, up 5.6%
• Constant currency revenue* up 6.6%
• Constant currency revenue, organic,* up 5.0%
• GAAP operating margin of 13.6%, compared to 9.0% in prior year period
• Non-GAAP operating margin* of 20.1%, compared to 19.1% in prior year period
• GAAP EPS $0.61, up 75.7%
• Non-GAAP EPS* $0.92, up 16.8%

• Revenue and Earnings Guidance*

  	Updated Guidance(1)		Prior Guidance(2)
  Financial Measure	Year Ending	% Change	Year Ending	% Change
  ($, millions, except per share figures)	December 31, 2024	Y/Y	December 31, 2024	Y/Y
  Net Sales	$1,335 - $1,345	6% - 7%	$1,324 - $1,340	5% - 7%
  Cardiovascular Segment	$1,281 - $1,289	5% - 6%	$1,272 - $1,285	4% - 5%
  Endoscopy Segment	$54 - $56	45% - 52%	$53 - $56	45% - 51%
  Non-GAAP
  Earnings Per Share(3)	$3.27 - $3.35	15% - 17%	$3.22 - $3.31	13% - 16%

  *Percentage figures approximated; dollar figures may not foot due to rounding

  
  

  2024 Net Sales Guidance - % Change from Prior Year (Constant Currency) Reconciliation*

  	Updated Guidance(1)				Prior Guidance(2)
  	Low		High		Low		High
  2024 Net Sales Guidance - % Change from Prior Year (GAAP)	6.2%		7.0%		5.3%		6.6%
  Estimated impact of foreign currency exchange rate fluctuations	0.7%		0.7%		0.5%		0.5%
  2024 Net Sales Guidance - % Change from Prior Year (Constant Currency)	6.9%		7.7%		5.8%		7.1%

  *Percentage figures approximated and may not foot due to rounding

https://www.biospace.com/merit-medical-reports-second-quarter-2024-results-and-raises-full-year-guidance